Posts Tagged: ctDNA


This year’s top liquid biopsy conferences around the world

One of the most-discussed technologies of 2015 was liquid biopsy-based translational research and its future importance in precision medicine. In 2016, even more dedicated conferences will focus on liquid biopsy, with leaders in industry and academia discussing the potential of this essential tool of personalized healthcare going forward. As I have been following this topic very closely over the last year, I… Read article →


The Future’s So Bright: Liquid Biopsy in 2016

Basic scientists, clinicians and market analysts are all optimistic about the prospects for liquid biopsy in 2016. Several reports have determined that liquid biopsy is a growing market segment for cancer diagnosis and management (1–2), expected to reach $20 billion in the next five years (1). Biotech startups and major companies alike have jumped in… Read article →


Tackle the challenges of circulating tumor DNA (ctDNA) research and non-invasive prenatal testing (NIPT)

At the frontier of liquid biopsy, NIPT (noninvasive prenatal testing) is increasingly being used to screen and test chromosomal abnormalities by analyzing cell-free fetal DNA circulating in maternal blood. Similarly, since disease-specific mutations or alterations of the circulating cell-free DNA (cfDNA) are frequently found in serum samples of cancer patients, research into cctDNA testing as… Read article →